Table 2.
Patient characteristics according to sentinel lymph node status
| SLN status* | All patients (n = 257)† | |||
|---|---|---|---|---|
| Negative (n = 226) | Positive (n = 31) | P | ||
| Year of surgery | 0·915 | |||
| Before 2003 | 42 (89) | 5 (11) | 47 (18·3) | |
| 2003–2006 | 111 (88·1) | 15 (11·9) | 126 (49·0) | |
| 2007–2010 | 73 (87) | 11 (13) | 84 (32·7) | |
| Age (years) | 0·079 | |||
| < 50 | 91 (82·7) | 19 (17·3) | 110 (42·8) | |
| 50–59 | 69 (91) | 7 (9) | 76 (29·6) | |
| ≥ 60 | 66 (93) | 5 (7) | 71 (27·6) | |
| Menopausal status | 0·030 | |||
| Premenopausal | 99 (83·2) | 20 (16·8) | 119 (46·3) | |
| Postmenopausal | 127 (92·0) | 11 (8·0) | 138 (53·7) | |
| Histology | 0·177 | |||
| Ductal | 203 (86·8) | 31 (13·2) | 234 (91·1) | |
| Lobular | 8 (100) | 0 (0) | 8 (3·1) | |
| Other | 15 (100) | 0 (0) | 15 (5·8) | |
| Grade | 0·511 | |||
| G1 | 36 (88) | 5 (12) | 41 (16·0) | |
| G2 | 87 (90) | 10 (10) | 97 (37·7) | |
| G3 | 83 (85) | 15 (15) | 98 (38·1) | |
| Unknown | 20 (95) | 1 (5) | 21 (8·2) | |
| Subtype | 0·387 | |||
| Unknown | 23 (88) | 3 (12) | 26 (10·1) | |
| Luminal A | 70 (91) | 7 (9) | 77 (30·0) | |
| Luminal B (Ki67 ≥ 20%) | 22 (81) | 5 (19) | 27 (10·5) | |
| Luminal B (HER2-positive) | 22 (88) | 3 (12) | 25 (9·7) | |
| HER2-positive | 66 (90) | 7 (10) | 73 (28·4) | |
| Triple negative | 23 (79) | 6 (21) | 29 (11·3) | |
| Local treatment | 0·206 | |||
| Mastectomy without radiotherapy | 49 (82) | 11 (18) | 60 (23·3) | |
| Mastectomy with radiotherapy | 27 (87) | 4 (13) | 31 (12·1) | |
| Quadrantectomy with radiotherapy | 150 (90·4) | 16 (9·6) | 166 (64·6) | |
| Systemic treatment | < 0·001 | |||
| None | 109 (93·2) | 8 (6·8) | 117 (45·5) | |
| Endocrine therapy | 110 (89·4) | 13 (10·6) | 123 (47·9) | |
| Chemotherapy | 5 (36) | 9 (64) | 14 (5·4) | |
| Chemotherapy + endocrine therapy | 2 (67) | 1 (33) | 3 (1·2) | |
Values in parentheses are percentages of
*
row and.
†
column. SLN, sentinel lymph node; HER2, human epidermal growth factor receptor 2.